JP2025512373A - 多価タンパク質-ヒアルロン酸ポリマーコンジュゲートを用いてぶどう膜炎を治療する方法 - Google Patents
多価タンパク質-ヒアルロン酸ポリマーコンジュゲートを用いてぶどう膜炎を治療する方法 Download PDFInfo
- Publication number
- JP2025512373A JP2025512373A JP2024560278A JP2024560278A JP2025512373A JP 2025512373 A JP2025512373 A JP 2025512373A JP 2024560278 A JP2024560278 A JP 2024560278A JP 2024560278 A JP2024560278 A JP 2024560278A JP 2025512373 A JP2025512373 A JP 2025512373A
- Authority
- JP
- Japan
- Prior art keywords
- subscript
- integer
- seq
- subscripts
- sum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263331554P | 2022-04-15 | 2022-04-15 | |
| US63/331,554 | 2022-04-15 | ||
| PCT/US2023/065779 WO2023201337A2 (en) | 2022-04-15 | 2023-04-14 | Method of treating uveitis with multivalent protein-hyaluronic acid polymer conjugate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025512373A true JP2025512373A (ja) | 2025-04-17 |
| JP2025512373A5 JP2025512373A5 (https=) | 2026-04-21 |
Family
ID=88330394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024560278A Pending JP2025512373A (ja) | 2022-04-15 | 2023-04-14 | 多価タンパク質-ヒアルロン酸ポリマーコンジュゲートを用いてぶどう膜炎を治療する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250255972A1 (https=) |
| EP (1) | EP4507731A2 (https=) |
| JP (1) | JP2025512373A (https=) |
| KR (1) | KR20250005285A (https=) |
| AU (1) | AU2023252928A1 (https=) |
| CA (1) | CA3256208A1 (https=) |
| WO (1) | WO2023201337A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202602849A (zh) * | 2024-03-28 | 2026-01-16 | 日商日產化學股份有限公司 | 石墨烯連接化合物及場效電晶體生物檢測器 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220251185A1 (en) * | 2019-07-01 | 2022-08-11 | Valitor, Inc. | Hydrophilic linkers for multivalent peptide conjugates |
-
2023
- 2023-04-14 KR KR1020247037830A patent/KR20250005285A/ko active Pending
- 2023-04-14 WO PCT/US2023/065779 patent/WO2023201337A2/en not_active Ceased
- 2023-04-14 JP JP2024560278A patent/JP2025512373A/ja active Pending
- 2023-04-14 CA CA3256208A patent/CA3256208A1/en active Pending
- 2023-04-14 AU AU2023252928A patent/AU2023252928A1/en active Pending
- 2023-04-14 EP EP23789179.1A patent/EP4507731A2/en active Pending
- 2023-04-14 US US18/856,982 patent/US20250255972A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023201337A2 (en) | 2023-10-19 |
| WO2023201337A3 (en) | 2023-11-23 |
| CA3256208A1 (en) | 2023-10-19 |
| AU2023252928A1 (en) | 2024-10-24 |
| KR20250005285A (ko) | 2025-01-09 |
| EP4507731A2 (en) | 2025-02-19 |
| US20250255972A1 (en) | 2025-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7736577B2 (ja) | 多価ペプチドコンジュゲート用の親水性リンカー | |
| JP2021521111A (ja) | カンプトテシンペプチドコンジュゲート | |
| CN116271079B (zh) | 一种抗dll3抗体及其制备方法、其药物偶联物和应用 | |
| JP2022550851A (ja) | カンプトテシンペプチドコンジュゲート | |
| US20130259882A1 (en) | Conjugate of Folate and Antibody Preparation Method and Use Thereof | |
| HRP20050353A2 (en) | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | |
| CN103282055A (zh) | 抗糖尿病化合物 | |
| US20180371060A1 (en) | Modified pigment epithelium-derived factor (pedf) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | |
| CN109069581B (zh) | 锁环螺旋肽及合成方法 | |
| JP2025512373A (ja) | 多価タンパク質-ヒアルロン酸ポリマーコンジュゲートを用いてぶどう膜炎を治療する方法 | |
| US20230405133A1 (en) | Purified multivalent protein-hyaluronic acid polymer conjugates | |
| EP2496262A2 (en) | Stabilized protein formulations and use thereof | |
| CN115702004A (zh) | 具有cd3和cd19双重特异性的聚乙二醇化t细胞衔接器 | |
| TW202220700A (zh) | 包含三重升糖素/glp-1/gip受體促效劑的長效接合物的醫藥組成物 | |
| US20230406916A1 (en) | Humanized multivalent protein conjugates | |
| RU2855513C1 (ru) | Фармацевтическая композиция, содержащая длительно действующий конъюгат тройного агониста рецепторов глюкагона/GLP-1/GIP | |
| US20260097125A1 (en) | Ultra-long-acting platform comprising fc-advanced fatty acid chain | |
| KR102177339B1 (ko) | 경구용 유전자 전달체 및 이의 용도 | |
| HK40129608A (en) | Ultra-long-acting platform comprising fc-advanced fatty acid chain | |
| HK40101829A (zh) | 免疫调节抗体药物结合物 | |
| HK1189606A (en) | Conjugate of folate and antibody, preparation method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260413 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260413 |